European Antibody Congress 2016
The European Antibody Congress is where pharma, biotechs, clinicians, researchers & innovative start-ups gather to develop new strategies and partnerships to advance antibody drug discovery, development, and commercialisation. Join the largest antibody event focused on getting important new therapeutics and immunotherapies into the clinic and see where antibody development is headed next.
The European Antibody Congress 2016 will introduce a innovation zone to provide opportunities for the SMEs to get in front of key pharma, biotech and investors from the Antibody industry. 2016 will also see an increased focus on Immunotherpy as we look to welcome over 500 attendees to the European Antibody Congress 2016 and the co-located
World Biosimilar Congress 2016, World Immunotherapy Congress 2016 and HPAPI World Congress 2016.
Final standard price : GBP 2970
Final academic and regulatory price : GBP 1485
Speakers: Alain Beck, Senior Director, CIPF, Associate Editors, mABs, Andrew Polson, Principal Scientist, Genentech, Berthold Boedeker, Chief Scientist, Global Biologics Development, Bayer Pharma AG, Denise Karaoglu Hanzatian, Principal Research Scientist, AbbVie Bioresearch Centre, Herve Broly, Vice President Biotech Process Development, Merck Serono SA, Jiri Kovarik, Senior Research Investigator, Novartis Institutes for Biomedical Research, Olivier Heudi, Laboratory Head, Novartis Pharma AG, Thomas Sandal, VP of preclinical Development and Protein Engineering, Crescendo Biologics, Ulf Grawunder, CEO, NBE Therapeutics, Yasmina Abdiche, Head of Bioanalytical Group, Rinat Pfizer